Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer

Abstract Introduction Tarlatamab is a bispecific T-cell engager (BiTE®) immunotherapy that binds delta-like ligand 3 on the surface of small cell lung cancer (SCLC) cells and CD3 on T cells, facilitating T cell-mediated cancer cell lysis. In the primary analysis of the phase 2 DeLLphi-301 study (NCT...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Myung-Ju Ahn, Byoung Chul Cho, Kadoaki Ohashi, Hiroki Izumi, Jong-Seok Lee, Ji-Youn Han, Chi-Lu Chiang, Shuang Huang, Ali Hamidi, Sujoy Mukherjee, Krista Lin Xu, Hiraoki Akamatsu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2025-09-01
coleção:	Oncology and Therapy
Assuntos:	Small cell lung cancer (SCLC) Tarlatamab DLL3 Bispecific T-cell engager Asian patients
Acesso em linha:	https://doi.org/10.1007/s40487-025-00372-0
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!